Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -18.74% | -1.94% | -6.14% | 1.02% | -2.47% |
| Total Depreciation and Amortization | 8.91% | 29.32% | 50.99% | -0.78% | 20.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.47% | 0.97% | -2.54% | 25.49% | -1.97% |
| Change in Net Operating Assets | -5.64% | -27.47% | 139.72% | -8,049.70% | -100.52% |
| Cash from Operations | -24.26% | -5.54% | 22.66% | -14.06% | -176.47% |
| Capital Expenditure | 163.56% | -17.29% | -3.73% | -69.53% | 50.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -522.56% | -40.13% | -37.15% | 128.76% | -493.55% |
| Cash from Investing | -560.14% | -43.05% | -38.38% | 127.77% | -511.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,360,463.64% | 120.00% | -87.95% | -72.15% | -99.91% |
| Repurchase of Common Stock | 4.17% | 25.00% | 81.77% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 123,683.06% | 29.24% | 81.49% | -720.13% | -99.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 579.14% | -227.78% | -63.93% | 108.54% | -200.50% |